Browsing Tag
AstraZeneca
154 posts
New Baxdrostat Phase III data reveal significant ambulatory blood pressure reduction in resistant patients
Find out how AstraZeneca’s Baxdrostat achieved significant blood pressure reductions in resistant hypertension patients in Phase III trials.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Novavax offloads Maryland site to AstraZeneca for $59.8m—what does it mean for both companies?
Find out how Novavax’s Gaithersburg site transfer to AstraZeneca for $59.8M fits into its strategic refocus and what this means for future manufacturing shifts.
Tezspire gains FDA approval for CRSwNP, expanding AstraZeneca and Amgen’s reach in inflammatory airway diseases
Tezspire gets FDA approval for chronic rhinosinusitis with nasal polyps. See how AstraZeneca and Amgen are expanding the respiratory biologics frontier.
Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today.
TROPION-PanTumor03 trial reports breakthrough responses with DATROWAY and Rilvegostomig combo in bladder cancer
Discover how DATROWAY plus rilvegostomig is rivaling the EV-302 standard with high response rates in metastatic urothelial cancer.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Trump announces second MFN pricing deal as AstraZeneca slashes drug costs for millions
AstraZeneca to offer most-favored-nation drug prices to U.S. Medicaid and invest $50B in American pharma manufacturing. Find out what it means for patients.
AstraZeneca strikes $50bn U.S. deal to lower drug prices while reshoring manufacturing amid tariff freeze
AstraZeneca inks $50B U.S. deal to cut drug prices and boost onshore manufacturing. See what this means for patients, profits, and pharma’s policy future.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.